{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T11:56:53Z","timestamp":1782561413454,"version":"3.54.5"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Colloid and Interface Science"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.jcis.2016.01.012","type":"journal-article","created":{"date-parts":[[2016,1,7]],"date-time":"2016-01-07T02:15:19Z","timestamp":1452132919000},"page":"180-191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Exploitation of redox discrepancy in leukemia cells by a reactive oxygen species nanoscavenger for inducing cytotoxicity in imatinib resistant cells"],"prefix":"10.1016","volume":"467","author":[{"given":"Sarbari","family":"Acharya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeeb K.","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcis.2016.01.012_b0005","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2040620712468289","article-title":"Management of imatinib-resistant patients with chronic myeloid leukemia","volume":"4","author":"Bhamidipati","year":"2013","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.jcis.2016.01.012_b0010","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jcis.2016.01.012_b0015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fphar.2013.00028","article-title":"Mechanisms and insights into drug resistance in cancer","volume":"4","author":"Zahreddine","year":"2013","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jcis.2016.01.012_b0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"Bixby","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jcis.2016.01.012_b0025","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2005-10-4020","article-title":"Complex interaction of BCRP\/ABCG2 and imatinib in BCR-ABL-expressing cells: BCRP-mediated resistance to imatinib is attenuated by imatinib-induced reduction of BCRP expression","volume":"108","author":"Nakanishi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jcis.2016.01.012_b0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/ars.2008.2095","article-title":"Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities","volume":"11","author":"Kuo","year":"2009","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.jcis.2016.01.012_b0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/toxsci\/kfn267","article-title":"Increased Nrf2 activation in livers from Keap1-knockdown mice increases expression of cytoprotective genes that detoxify electrophiles more than those that detoxify reactive oxygen species","volume":"108","author":"Reisman","year":"2009","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.jcis.2016.01.012_b0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","article-title":"BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance","volume":"108","author":"Koptyra","year":"2006","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.jcis.2016.01.012_b0045","first-page":"S128","article-title":"Direct and indirect antioxidant properties of inducers of cytoprotective proteins","volume":"52","author":"Dinkova-Kostova","year":"2008","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.jcis.2016.01.012_b0050","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1517\/17425247.2012.724676","article-title":"Emerging role of nanocarriers to increase the solubility and bioavailability of curcumin","volume":"9","author":"Mohanty","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jcis.2016.01.012_b0055","doi-asserted-by":"crossref","first-page":"6597","DOI":"10.1016\/j.biomaterials.2010.04.062","article-title":"The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation","volume":"31","author":"Mohanty","year":"2010","journal-title":"Biomaterials"},{"key":"10.1016\/j.jcis.2016.01.012_b0060","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.drudis.2012.05.010","article-title":"Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy","volume":"17","author":"Parhi","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jcis.2016.01.012_b0065","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.bcp.2012.01.008","article-title":"Nanoparticle-based combination therapy toward overcoming drug resistance in cancer","volume":"83","author":"Hu","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jcis.2016.01.012_b0070","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jcis.2016.01.012_b0075","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1021\/mp100455h","article-title":"Coformulation of doxorubicin and curcumin in poly(D, L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells","volume":"8","author":"Misra","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jcis.2016.01.012_b0080","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejps.2009.11.010","article-title":"Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy","volume":"39","author":"Misra","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jcis.2016.01.012_b0085","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1016\/j.biomaterials.2009.07.008","article-title":"Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy","volume":"30","author":"Acharya","year":"2009","journal-title":"Biomaterials"},{"key":"10.1016\/j.jcis.2016.01.012_b0090","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.nano.2014.09.002","article-title":"Multifunctional nanoparticle-EpCAM aptamer bioconjugates: a paradigm for targeted drug delivery and imaging in cancer therapy","volume":"11","author":"Das","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jcis.2016.01.012_b0095","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jcis.2015.03.049","article-title":"Trastuzumab guided nanotheranostics: a lipid based multifunctional nanoformulation for targeted drug delivery and imaging in breast cancer therapy","volume":"451","author":"Parhi","year":"2015","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jcis.2016.01.012_b0100","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1016\/j.febslet.2006.02.020","article-title":"Mechanisms and strategies to overcome multiple drug resistance in cancer","volume":"580","author":"Ozben","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jcis.2016.01.012_b0105","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/leu.2009.233","article-title":"Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells","volume":"24","author":"Puissant","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.jcis.2016.01.012_b0110","first-page":"3183","article-title":"Superoxide dismutases in gastric and esophageal cancer and the prognostic impact in gastric cancer","volume":"6","author":"Janssen","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jcis.2016.01.012_b0115","first-page":"373","article-title":"Controlled delivery of Imatinib mesylate from collagen-coated poly (lactic acid) microspheres: in vitro release studies","volume":"6","author":"Babu","year":"2014","journal-title":"Int. J. Drug Delivery"},{"key":"10.1016\/j.jcis.2016.01.012_b0120","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s11706-014-0270-8","article-title":"Fabrication and characterization of curcumin-loaded silk fibroin\/P(LLA-CL) nanofibrous scaffold","volume":"8","author":"Lian","year":"2014","journal-title":"Front. Mater. Sci."},{"key":"10.1016\/j.jcis.2016.01.012_b0125","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/138920012798356952","article-title":"Design of curcumin loaded cellulose nanoparticles for prostate cancer","volume":"13","author":"Yallapu","year":"2012","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.jcis.2016.01.012_b0130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jconrel.2009.01.018","article-title":"Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles","volume":"135","author":"Nam","year":"2009","journal-title":"J. Control Release"},{"key":"10.1016\/j.jcis.2016.01.012_b0135","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1096\/fj.02-0088com","article-title":"Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery","volume":"16","author":"Panyam","year":"2002","journal-title":"Faseb J."},{"key":"10.1016\/j.jcis.2016.01.012_b0140","doi-asserted-by":"crossref","first-page":"6434","DOI":"10.1038\/onc.2008.310","article-title":"Lysosomal membrane permeabilization in cell death","volume":"27","author":"Boya","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.jcis.2016.01.012_b0145","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3390\/cancers3021605","article-title":"The role of nrf2 and cytoprotection in regulating chemotherapy resistance of human leukemia cells","volume":"3","author":"Rushworth","year":"2011","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jcis.2016.01.012_b0150","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.critrevonc.2005.06.007","article-title":"Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)","volume":"57","author":"Christoph","year":"2006","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"10.1016\/j.jcis.2016.01.012_b0155","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/2278-330X.126553","article-title":"Is imatinib still the best choice as first-line oral TKI","volume":"3","author":"Bansal","year":"2014","journal-title":"South Asian J. Cancer"},{"key":"10.1016\/j.jcis.2016.01.012_b0160","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1472-6882-12-61","article-title":"Natural resistance to ascorbic acid induced oxidative stress is mainly mediated by catalase activity in human cancer cells and catalase-silencing sensitizes to oxidative stress","volume":"12","author":"Klingelhoeffer","year":"2012","journal-title":"BMC Complement Alternative Med."},{"key":"10.1016\/j.jcis.2016.01.012_b0165","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/1541-7786.MCR-11-0378","article-title":"Acquisition of resistance of pancreatic cancer cells to 2-methoxyestradiol is associated with the upregulation of manganese superoxide dismutase","volume":"10","author":"Zhou","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.jcis.2016.01.012_b0170","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4161\/cbt.4.4.1698","article-title":"Reversal of multidrug resistance in KB cells with tea polyphenol antioxidant capacity","volume":"4","author":"Mei","year":"2005","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.jcis.2016.01.012_b0175","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1021\/nn4007048","article-title":"Lysosomal membrane permeabilization by targeted magnetic nanoparticles in alternating magnetic fields","volume":"7","author":"Domenech","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.jcis.2016.01.012_b0180","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10495-006-3486-y","article-title":"Cathepsin-regulated apoptosis","volume":"11","author":"Chwieralski","year":"2006","journal-title":"Apoptosis"},{"key":"10.1016\/j.jcis.2016.01.012_b0185","doi-asserted-by":"crossref","first-page":"e107158","DOI":"10.1371\/journal.pone.0107158","article-title":"The sensitivity of cancer cells to pheophorbide a-based photodynamic therapy is enhanced by Nrf2 silencing","volume":"9","author":"Choi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jcis.2016.01.012_b0190","doi-asserted-by":"crossref","first-page":"e88359","DOI":"10.1371\/journal.pone.0088359","article-title":"Astaxanthin treatment confers protection against oxidative stress in U937 cells stimulated with lipopolysaccharide reducing O2\u2212 production","volume":"9","author":"Franceschelli","year":"2013","journal-title":"PLoS One"}],"container-title":["Journal of Colloid and Interface Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021979716300121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021979716300121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:14:56Z","timestamp":1572480896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021979716300121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":38,"alternative-id":["S0021979716300121"],"URL":"https:\/\/doi.org\/10.1016\/j.jcis.2016.01.012","relation":{},"ISSN":["0021-9797"],"issn-type":[{"value":"0021-9797","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploitation of redox discrepancy in leukemia cells by a reactive oxygen species nanoscavenger for inducing cytotoxicity in imatinib resistant cells","name":"articletitle","label":"Article Title"},{"value":"Journal of Colloid and Interface Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcis.2016.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}